Advarra

JANUARY 11, 2024

Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials. The mRNA constructs used in COVID-19 vaccines, for example, direct cells to produce a version of the “spike” protein studding the surface of SARS-CoV-2.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

XTalks

MARCH 6, 2024

This includes discussions on cutting-edge technologies and methodologies in brain research, such as neuroimaging, genetic engineering and artificial intelligence. Boston Scientific’s Deep Brain Stimulation (DBS) Software received FDA approval last year for the treatment of Parkinson’s disease and essential tremor.

FDA Approval 69

FDA Approval In-Vitro Research Marketing 69

The Pharma Data

NOVEMBER 9, 2020

Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate. Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant. Source: Novavax, Inc. .

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

XTalks

AUGUST 17, 2020

protein-based biologics) and vaccine treatments. protein-based biologics) : are those which bind to specific components (i.e. In 2017, the US FDA approved a CAR-T cell treatment for young adults and children with B-cell ALL. chimeric receptor antigen [CAR] T cell) immune modulators (i.e. Immune system modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

The Pharma Data

NOVEMBER 30, 2020

CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with Novavax’ proprietary Matrix?M. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. The award is funding the U.S.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

XTalks

MARCH 28, 2024

Gene Editing and CAR T-Cell Therapy Genetic engineering technologies, such as CRISPR-Cas9, are providing newer potential avenues for cancer treatment. Tukysa (tucatinib) plus Herceptin (trastuzumab): The FDA has approved this treatment for certain individuals with CRC characterized by overexpression of HER2 proteins in their tumors.

Gene Editing 59

Gene Editing Life Science Clinical Trials Clinical Trials 59

XTalks

SEPTEMBER 15, 2022

The US Food and Drug Administration (FDA) approved the first genetically engineered crops nearly 30 years ago with the Rainbow papaya — created with an immunity to a virus that threatened to decimate the crop — and the Flavr Savr tomato. Biotechnology is also taking on new forms in food.

FDA Approval 95

FDA Approval Genetic Engineering Genetics Production 95